-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] July 28 is the twelfth World Hepatitis D.
Hepatitis is an inflammation of the liver caused by viruses, bacteria, parasites, chemical poisons, alcohol, autoimmune diseases and other facto.
According to the cause, it can be divided into viral hepatitis, such as five types of hepatitis A, B, C, D and E, and non-viral hepatitis, such as alcoholic hepatitis, steatohepatitis, drug-induced hepatitis, autoimmune Hepatitise.
The liver is an important detoxification organ in the human body and a digestive gland in the body, which plays an important role in the transfer of human metaboli.
Strengthening the protection of the liver is very importa.
Nowadays, there are a large number of known liver disease patients in China, and there is a huge demand for liver disease drugs in the mark.
Analysts said that with the introduction of mainstream antiviral drugs into centralized procurement and the expiration of patents, relevant domestic companies are expected to become the successors of the liver disease drug market in the futu.
For example, in the A-share market, Sunflower Pharmaceutical Sunflower Hugan Tablets have the functions of soothing the liver and regulating qi, invigorating the spleen and digestion, and reducing transamina.
Clinically, it is used for fatty liver, alcoholic liver, drug-induced liver injury, chronic hepatitis and early liver disea.
Prevention and treatment of cirrhosis; Saisheng Pharmaceutical's thymosin for injection indications include various types of severe hepatitis, chronic active hepatitis, chronic persistent hepatitis and liver cirrhosis; Fangsheng Pharmaceutical's new traditional Chinese medicine for the treatment of viral hepatitis B - Yigan Qingdu Granules The clinical trial research project belongs to the “Twelfth Five-Year Plan” “Major New Drug Creation” proje.
It is understood that in order to bring better drug treatment to more hepatitis patients, pharmaceutical companies have also continued to strengthen product innovation and research and development, and some companies have also made key breakthroug.
For example, Guangshengtang recently announced that the first subject of the Phase I clinical trial of its innovative drug holding subsidiary Guangsheng Zhonglin hepatitis B treatment new drug GST-HG121 was enrolled and administered on July 26, 2022, marking GST -The clinical trial of the HG121 project has entered a substantial development peri.
The data show that GST-HG121 is a new type of anti-HBV drug with a brand-new target, and it is a global First-in-Class proje.
The decline of HBsAg and the realization of immune recovery are considered to be the key to challenging the clinical cure of hepatiti.
GST-HG121 is one of the important components of Guangshengtang's Hepatitis B clinical cure "Dengfeng Pla.
In addition, in the field of liver disease drugs, Chia Tai Tianqing has also continuously strengthened the research and development of related dru.
For example, as early as 1988, Lianyungang Dongfeng Pharmaceutical Factory (later Chia Tai Tianqing) cooperated to develop a liver disease drug, Qiangli Ning, and thus made the research and development and industrialization of liver disease drugs as the leading development direction of the enterprise; in 2005, Chia Tai Tianqing’s Class 1 new drug, Tianqing Ganmei, has been approved for marketi.
The current sales amount exceeds 1 billion yu.
It belongs to the brand of liver injury drugs for injecti.
And in August 2021, the co-operation between Chia Tai Tianqing and Kangfang Biopharmaceuticals was approved for marketing of Piamprimab (anti-PD-1 monoclonal antibody), which successfully completed the listing of indications including non-small cell lung cancer and nasopharyngeal canc.
Application; hepatocellular carcinoma, gastric cancer, gastroesophageal junction cancer, e.
are in the phase III clinical research sta.
Data shows that there are currently as many as 64 listed companies involved in liver disease treatment and testing in the A-share market, with a total market value of over 700 billion yu.
However, from the current point of view, there is no specific drug for liver disea.
Some research reports point out that once a breakthrough drug with a high cure rate appears, the domestic liver disease drug will reach a market size of 100 billion in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Hepatitis is an inflammation of the liver caused by viruses, bacteria, parasites, chemical poisons, alcohol, autoimmune diseases and other facto.
According to the cause, it can be divided into viral hepatitis, such as five types of hepatitis A, B, C, D and E, and non-viral hepatitis, such as alcoholic hepatitis, steatohepatitis, drug-induced hepatitis, autoimmune Hepatitise.
The liver is an important detoxification organ in the human body and a digestive gland in the body, which plays an important role in the transfer of human metaboli.
Strengthening the protection of the liver is very importa.
Nowadays, there are a large number of known liver disease patients in China, and there is a huge demand for liver disease drugs in the mark.
Analysts said that with the introduction of mainstream antiviral drugs into centralized procurement and the expiration of patents, relevant domestic companies are expected to become the successors of the liver disease drug market in the futu.
For example, in the A-share market, Sunflower Pharmaceutical Sunflower Hugan Tablets have the functions of soothing the liver and regulating qi, invigorating the spleen and digestion, and reducing transamina.
Clinically, it is used for fatty liver, alcoholic liver, drug-induced liver injury, chronic hepatitis and early liver disea.
Prevention and treatment of cirrhosis; Saisheng Pharmaceutical's thymosin for injection indications include various types of severe hepatitis, chronic active hepatitis, chronic persistent hepatitis and liver cirrhosis; Fangsheng Pharmaceutical's new traditional Chinese medicine for the treatment of viral hepatitis B - Yigan Qingdu Granules The clinical trial research project belongs to the “Twelfth Five-Year Plan” “Major New Drug Creation” proje.
It is understood that in order to bring better drug treatment to more hepatitis patients, pharmaceutical companies have also continued to strengthen product innovation and research and development, and some companies have also made key breakthroug.
For example, Guangshengtang recently announced that the first subject of the Phase I clinical trial of its innovative drug holding subsidiary Guangsheng Zhonglin hepatitis B treatment new drug GST-HG121 was enrolled and administered on July 26, 2022, marking GST -The clinical trial of the HG121 project has entered a substantial development peri.
The data show that GST-HG121 is a new type of anti-HBV drug with a brand-new target, and it is a global First-in-Class proje.
The decline of HBsAg and the realization of immune recovery are considered to be the key to challenging the clinical cure of hepatiti.
GST-HG121 is one of the important components of Guangshengtang's Hepatitis B clinical cure "Dengfeng Pla.
In addition, in the field of liver disease drugs, Chia Tai Tianqing has also continuously strengthened the research and development of related dru.
For example, as early as 1988, Lianyungang Dongfeng Pharmaceutical Factory (later Chia Tai Tianqing) cooperated to develop a liver disease drug, Qiangli Ning, and thus made the research and development and industrialization of liver disease drugs as the leading development direction of the enterprise; in 2005, Chia Tai Tianqing’s Class 1 new drug, Tianqing Ganmei, has been approved for marketi.
The current sales amount exceeds 1 billion yu.
It belongs to the brand of liver injury drugs for injecti.
And in August 2021, the co-operation between Chia Tai Tianqing and Kangfang Biopharmaceuticals was approved for marketing of Piamprimab (anti-PD-1 monoclonal antibody), which successfully completed the listing of indications including non-small cell lung cancer and nasopharyngeal canc.
Application; hepatocellular carcinoma, gastric cancer, gastroesophageal junction cancer, e.
are in the phase III clinical research sta.
Data shows that there are currently as many as 64 listed companies involved in liver disease treatment and testing in the A-share market, with a total market value of over 700 billion yu.
However, from the current point of view, there is no specific drug for liver disea.
Some research reports point out that once a breakthrough drug with a high cure rate appears, the domestic liver disease drug will reach a market size of 100 billion in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
